Watch HALO. Know when insiders buy.
One email the day a filing lands. Free.
HALO
HALOZYME THERAPEUTICS, INC.
124.83
+0.46 +0.37%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
36
FLAG · insiders 25, shorts 46
Insiders, 90 days
−$15.7M
net selling · 0 buys, 27 sells
Congress, 90 days
0 / 1
buys / sells · latest disclosed Oct 12
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $14.2BP/E 36.4DIV YIELD —FCF YIELD 5.69%REV TTM $1.7B +41.2%NET INCOME $413.6M −25.8%NET DEBT $2B52W 61.63 – 124.83NEXT EARNINGS Nov 2 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $481M | +47.7% | 83.5% | $287.7M | $229.9M | +39.2% | 1.90 | $240.9M | $4.2M | $236.7M | Aug 6 |
| Q1 2026 · Mar 31 | $376.7M | +42.2% | 79.0% | $184.5M | $150M | +27.1% | 1.22 | $180.1M | $3.7M | $176.3M | May 11 |
| Q4 2025 · Dec 31derived | $451.8M | +51.6% | 82.6% | −$92.9M | −$141.6M | −203.3% | -1.12 | $219M | $1.4M | $217.6M | Feb 17 |
| Q3 2025 · Sep 30 | $354.3M | +22.1% | 84.4% | $217.9M | $175.2M | +27.9% | 1.43 | $178.6M | $3M | $175.6M | Nov 3 |
| Q2 2025 · Jun 30 | $325.7M | +40.8% | 85.8% | $202.4M | $165.2M | +77.1% | 1.33 | $99.7M | $1.6M | $98.1M | Aug 6 |
| Q1 2025 · Mar 31 | $264.9M | +35.2% | 81.7% | $141.5M | $118.1M | +53.7% | 0.93 | $154.2M | $950K | $153.3M | May 11 |
| Q4 2024 · Dec 31derived | $298M | +29.5% | 85.9% | $175.5M | $137M | +60.5% | 1.06 | $178.5M | $3.1M | $175.4M | Feb 17 |
| Q3 2024 · Sep 30 | $290.1M | +34.3% | 83.0% | $163.2M | $137M | +67.4% | 1.05 | $115.4M | $1.5M | $113.9M | Nov 3 |
| Q2 2024 · Jun 30 | $231.4M | — | 82.9% | $117.2M | $93.2M | — | 0.72 | $55.8M | $2.6M | $53.2M | Aug 5 |
| Q1 2024 · Mar 31 | $195.9M | — | 85.5% | $95.5M | $76.8M | — | 0.60 | $129.4M | $3.5M | $125.9M | May 6 |
| Q4 2023 · Dec 31derived | $230M | — | 77.3% | $101M | $85.4M | — | 0.65 | $102.4M | $2.6M | $99.8M | Feb 17 |
| Q3 2023 · Sep 30 | $216M | — | 74.6% | $88.3M | $81.8M | — | 0.61 | $132.4M | $2.9M | $129.5M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.4B | 83.6% | $469M | $316.9M | 22.7% | 2.56 | $651.6M | $7M | $644.6M | $342.4M | — |
| FY2024 · to Dec 31 | $1B | 84.3% | $551.5M | $444.1M | 43.7% | 3.43 | $479.1M | $10.7M | $468.4M | $250M | — |
| FY2023 · to Dec 31 | $829.3M | 76.8% | $337.6M | $281.6M | 34.0% | 2.10 | $388.6M | $15.3M | $373.3M | $402.4M | — |
| FY2022 · to Dec 31 | $660.1M | 78.9% | $267.5M | $202.1M | 30.6% | 1.44 | $240.1M | $4.8M | $235.3M | $200M | — |
| FY2021 · to Dec 31 | $443.3M | 81.6% | $275.9M | $402.7M | 90.8% | 2.74 | $299.4M | $1.5M | $298M | $350.1M | — |
| FY2020 · to Dec 31 | $267.6M | 83.8% | $144.3M | $129.1M | 48.2% | 0.91 | $55.5M | $2.5M | $53M | $150.1M | — |
Every number comes from HALOZYME THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.